Gubra company profile
Company profile
Gubra has 330 employees and is headquartered in Horsholm, Denmark.
Based in Horsholm, Denmark, and founded in 2008, Gubra works in peptide-based drug discovery and preclinical contract research. Its contract research and development services cover metabolic and fibrotic diseases and are offered to pharmaceutical and biotechnology companies in Europe, North America and other international markets. The services include in vivo pharmacology, biomarker assays, bioinformatics, next generation sequencing and histology with artificial intelligence pathology. Alongside these services, the company holds a portfolio of potential drug candidates that generates upfront, research and milestone payments and royalties, and it invests in assets promoting the green transition through its Gubra Green segment. Its collaborations include Boehringer Ingelheim on obesity, Camurus on hypoparathyroidism and Amylyx Pharmaceuticals on post-bariatric hypoglycemia.
In the fiscal year ended 31 December 2025, Gubra reported revenue of DKK 2.6 billion and net profit of DKK 1.7 billion. The company had 330 employees, and its headquarters are in Horsholm.
Company facts
- Sector
- Industrials
- Industry
- Biotechnology
- Country
- Denmark
- Headquarters
- HOersholm Kongevej 11B, 2970, Horsholm
- Employees
- 330
- Chief executive
- Markus Rohrwild
- Founded
- 2008
- Fiscal year
- January - December
- Listing
- GUBRA · Nasdaq Copenhagen
- Currency
- DKK
- ISIN
- DK0062266474
- Website
- gubra.dk
Gubra and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| GubraGUBRA | Denmark | $730.02M | 330 | -73.1% | — |
| DBV TechnologiesDBV | France | $572.52M | 179 | -5,577.0% | — |
| Pharming GroupPHARM | Netherlands | $841.25M | 407 | 12.8% | 36.1 |
| InventivaIVA | France | $890.8M | 87 | -5,980.9% | — |
| PhilogenPHIL | Italy | $905.96M | 230 | 79.1% | 3.67 |
| Basilea PharmaceuticaBSLN | Switzerland | $1.07B | 200 | 24.2% | 18.1 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
